HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Q2 Consumer Health Earnings Preview: Two Firsts On Table For Perrigo, One For Kenvue

Executive Summary

Perrigo will note regulatory approval for Opill as first US OTC oral contraceptive in first earnings briefing with Patrick Lockwood-Taylor at helm. Other firsts in sector will be Kenvue’s 20 July results being its first since spin-out from J&J in May and Bausch + Lomb’s first quarterly results under CEO Saunders.

You may also be interested in...

Right Guard Antiperspirant Owners To Compensate Purchasers Nationwide In $1.95m Benzene Settlement

Henkel and Thriving Brands admit no wrongdoing, but have agreed to settle allegations in Connecticut federal court that they knowingly or negligently sold US consumers adulterated and misbranded antiperspirant products containing hazardous levels of benzene.

First OTC Birth Control Pill Approved In US Will Launch With Three-Year Market Exclusivity

FDA approval of Perrigo subsidiary HRA’s application comes 60 years after Rx birth control was approved in the US, one year after the application was submitted, and 13 months after the Supreme Court’s Dobbs ruling. Perrigo plans to launch sales in 2024 first quarter.

In J&J’s ‘Mutually Beneficial’ Frame For Selling Blink OTC Eye Drops To B+L, Kenvue Also Wins

In second buy in a week, B+L paying $106.5m in cash deal for products marketed by Johnson & Johnson Vision. Acquired products are Blink Tears lubricating eye drops and Blink Contacts and Blink-N-Clean lens drops.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts